PTC Therapeutics, Inc.

NASDAQ:PTCT

Biotechnology

Healthcare
$60.23 +0.76%

+$0.60 today

Market cap
$5.03B
Beta
0.55
P/E (TTM)
-35.0
EPS (TTM)
-$2.26
52W Low $43.18High $87.50

Volume 0.64M

Average 1.27M

PTCT Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

PTC Therapeutics, Inc.NASDAQ: PTCT

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin dips below year-ago levels

Q2 FY2026 selling, general & admin of $80.63M fell 5.4% year over year, behind the +8.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 6.4% from the prior quarter. Over 3 fiscal years it compounded at +2.1% a year.

Context

  • Selling, general & admin amounted to 20.1% of revenue in FY2025, down 17.2 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 10 analysts of $508.16M (+46.4%) for the fiscal year ending Dec 2026, a step up from the +15.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$80.63M-6.4% QoQ
Last fiscal yearDec 2025
$347.14M+15.4% YoY
LTMJun 2026
$351.33M+8.3% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.4%+40.4%+45.8 pp
1 year+15.4%+46.4%+31.0 pp
3-year CAGR+2.1%+21.8%+19.7 pp
5-year CAGR+16.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
347.14M USD
Year-over-year change
+15.4%
4-year CAGR
+5.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How PTCT compares with its peers on the latest reported figures

  • PTCT's LTM Jun 2026 selling, general & admin of $351.33M is the 5th highest of the 11 companies compared; the peer median is $254.99M.
  • Its year-over-year change of +8.3% is the 9th highest of 11, against a peer median of +37.7%.
  • Selling, general & admin amounts to 34.8% of revenue for PTCT, versus a peer median of 52.3%.
PTCT Competitors Peer median
Selling, General & Admin for PTCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$335.1B +34325.1%+15.8%32.6%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$669.78M +67.8%+57.1%93.9%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$584.98M +66.3%+37.9%61.0%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$467.04M -17.3%+2.0%21.4%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$351.33M +8.3%+2.1%34.8%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$350.27M +5.7%+7.9%52.3%
KRYSKrystal Biotech, Inc.LTM Jun 2026$159.72M +24.9%+23.6%36.3%
DYNDyne Therapeutics, Inc.LTM Jun 2026$91.25M +50.5%+35.3%—
WVEWave Life Sciences Ltd.LTM Mar 2026$79.08M +23.9%+14.3%110.1%
SLDBSolid Biosciences Inc.LTM Mar 2026$40.91M +18.8%+10.3%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$26.76M +58.7%+29.7%—
Peer median (excluding PTCT) $254.99M+37.7%+19.7%52.3%

Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue538.59M698.8M937.82M806.78M1.73B
Cost of Revenue32.33M44.68M65.49M57.4M71.76M
Gross Profit506.27M654.12M872.34M749.38M1.66B
Gross Margin94.0%93.6%93.0%92.9%95.9%
Research & Development540.68M651.5M666.56M534.48M455.25M
Selling, General & Admin285.77M326M332.54M300.91M347.14M
Operating Expenses880.71M1.1B1.31B1.05B802.39M
Depreciation & Amortization64.13M128.84M236.59M75.66M38.82M
EBITDA(368.18M)(367.78M)(330.34M)(120.46M)887.66M
EBITDA Margin-68.4%-52.6%-35.2%-14.9%51.3%
Operating Income(374.44M)(447.41M)(439.5M)(302.57M)856.51M
Operating Margin-69.5%-64.0%-46.9%-37.5%49.5%
Interest Income00000
Interest Expense86.02M90.87M129.18M166.99M152.23M
Other Income / Expenses(143.9M)(140.08M)(256.61M)(60.55M)(159.89M)
Income Before Tax(518.34M)(587.49M)(696.11M)(363.12M)696.62M
Pre-Tax Margin-96.2%-84.1%-74.2%-45.0%40.3%
Income Tax Expense5.56M(28.47M)(69.51M)176K13.98M
Net Income(523.9M)(559.02M)(626.6M)(363.3M)682.64M
Net Margin-97.3%-80.0%-66.8%-45.0%39.4%
EPS (Basic)(7.43)(7.79)(8.37)(4.73)8.58
EPS (Diluted)(7.43)(7.79)(8.37)(4.73)7.78
Weighted Avg Shares70.47M71.73M74.84M76.85M79.53M
Weighted Avg Shares (Diluted)70.47M71.73M74.84M76.85M88.31M

PTC Therapeutics, Inc.

NASDAQ:PTCT

Intrinsic Alpha fair value

Locked

Current Price

$60.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.